# Takayuki Ohkuri

List of Publications by Year
in descending order



| 30 | 994 | 567281 15 | 526287 27 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 30 | 30 | 30 | 1783 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | STING Contributes to Antiglioma Immunity via Triggering Type I IFN Signals in the Tumor Microenvironment. Cancer Immunology Research, 2014, 2, 1199-1208. | 3.4 | 185 |
| 2 | Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site. Cancer Immunology, Immunotherapy, 2017, 66, 705-716. | 4.2 | 128 |
| 3 | Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy. Cancer Immunology, Immunotherapy, 2017, 66, 877-890. | 4.2 | 126 |
| 4 | Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts. , 2013, 1, 21. | | 85 |
| 5 | First clinical trial of cancer vaccine therapy with artificially synthesized helper/â€Škiller-hybrid epitope long peptide of MAGE-A4 cancer antigen. Cancer Science, 2012, 103, 150-153. | 3.9 | 53 |
| 6 | c-Met is a novel tumor associated antigen for T-cell based immunotherapy against NK/T cell lymphoma. OncoImmunology, 2015, 4, e976077. | 4.6 | 35 |
| 7 | Epigenetic modification augments the immunogenicity of human leukocyte antigen G serving as a tumor antigen for T cell-based immunotherapy. OncoImmunology, 2016, 5, e1169356. | 4.6 | 34 |
| 8 | IFN-Î³-dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. Carcinogenesis, 2009, 30, 1408-1415. | 2.8 | 33 |
| 9 | Effects of STING stimulation on macrophages: STING agonists polarize into â€œclassicallyâ€•or â€œalternativelyâ€•activated macrophages?. Human Vaccines and Immunotherapeutics, 2018, 14, 285-287. | 3.3 | 29 |
| 10 | CD47 blockade enhances the efficacy of intratumoral STING-targeting therapy by activating phagocytes. Journal of Experimental Medicine, 2021, 218, . | 8.5 | 27 |
| 11 | Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. Biochemical and Biophysical Research Communications, 2015, 458, 549-554. | 2.1 | 26 |
| 12 | Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine. Immunology Letters, 2014, 161, 20-30. | 2.5 | 24 |
| 13 | Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma. Scientific Reports, 2015, 5, 16280. | 3.3 | 22 |
| 14 | Intratumoral STING activations overcome negative impact of cisplatin on antitumor immunity by inflaming tumor microenvironment in squamous cell carcinoma. Biochemical and Biophysical Research Communications, 2020, 522, 408-414. | 2.1 | 19 |
| 15 | Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma. OncoImmunology, 2022, 11, 2021619. | 4.6 | 19 |
| 16 | Protective role of STING against gliomagenesis: Rational use of STING agonist in anti-glioma immunotherapy. OncoImmunology, 2015, 4, e999523. | 4.6 | 16 |
| 17 | Intratumoral injection of IFN-Î² induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb. Biochemical and Biophysical Research Communications, 2017, 490, 521-527. | 2.1 | 15 |
| 18 | Phosphorylated vimentin as an immunotherapeutic target against metastatic colorectal cancer. Cancer Immunology, Immunotherapy, 2020, 69, 989-999. | 4.2 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma. OncoImmunology, 2018, 7, e1466771. | 4.6 | 14 |
| 20 | PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma. Journal of Translational Medicine, 2019, 17, 207. | 4.4 | 13 |
| 21 | Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma. OncoImmunology, 2021, 10, 1856545. | 4.6 | 13 |
| 22 | Cyclin-dependent kinase 1 and survivin as potential therapeutic targets against nasal natural killer/T-cell lymphoma. Laboratory Investigation, 2019, 99, 612-624. | 3.7 | 12 |
| 23 | A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment. Cancer Immunology, Immunotherapy, 2021, 70, 2301-2312. | 4.2 | 11 |
| 24 | Interruption of MDM2 signaling augments MDM2-targeted T cell-based antitumor immunotherapy through antigen-presenting machinery. Cancer Immunology, Immunotherapy, 2021, 70, 3421-3434. | 4.2 | 11 |
| 25 | Identification of a meiosis-specific protein, MEIOB, as a novel cancer/testis antigen and its augmented expression in demethylated cancer cells. Immunology Letters, 2014, 158, 175-182. | 2.5 | 9 |
| 26 | IFN-Î³- and IL-17-producing CD8<sup>+</sup> T (Tc17-1) cells in combination with poly-ICLC and peptide vaccine exhibit antiglioma activity. , 2021, 9, e002426. | | 8 |
| 27 | A stealth antigen SPESP1, which is epigenetically silenced in tumors, is a suitable target for cancer immunotherapy. Cancer Science, 2021, 112, 2705-2713. | 3.9 | 6 |
| 28 | A tumor metastasisâ€associated molecule <scp>TWIST1</scp> is a favorable target for cancer immunotherapy due to its immunogenicity. Cancer Science, 2022, 113, 2526-2535. | 3.9 | 4 |
| 29 | Prognostic significance of OX40 <sup>+</sup> lymphocytes in tumor stroma of surgically resected small-cell lung cancer. OncoImmunology, 2021, 10, 1971430. | 4.6 | 2 |
| 30 | Innovative immunotherapy for nasal NK/T-cell lymphoma. Journal of Japan Society of Immunology & Allergology in Otolaryngology, 2018, 36, 15-22. | 0.0 | 0 |